Genentech to Continue Avastin Trial

Genentech(DNA Quote) said Monday that, after an interim analysis, a late-stage study of Avastin plus chemotherapy in patients with early-stage colon cancer will continue.

Final data from the study, which is testing Avastin as an adjuvant therapy in patients with colon cancer, are expected in mid-2009, according to the company.

The National Surgical Adjuvant Breast and Bowel Project (NSABP), which is handling the study, based the decision on a recommendation from an independent data monitoring committee following a planned review of the results. ...